Will Baxter's IV Solutions segment show positive organic revenue growth in Q2 2026?

Three lenses independently converged on the IV Solutions demand reset as permanent. Management itself described this as a 'new baseline' and is cutting workforce to align with lower demand. Clinical practice changes (fluid conservation, IV push) are embedded in hospital protocols with institutional inertia. For Q2 2026 to show positive organic growth, demand would need to have already bottomed and begun recovering — but the analysis found no evidence of recovery signals. The lapping of Hurricane Helene disruption (October 2024) would make Q2 2026 comparisons difficult since Q2 2025 was already at depressed levels.

The question is whether Q2 2026 benefits from easier YoY comparisons since Q2 2025 was post-hurricane. If Q2 2025 was already at depressed levels due to the October 2024 hurricane and subsequent demand reset, Q2 2026 could show positive organic growth simply from the comparison base rather than genuine demand recovery. This creates a technical path to YES without contradicting the permanent demand thesis. However, if the demand decline continued through Q2 2025, even the easier comparison may not produce positive growth.

The convergence across Gravy Gauge, Moat Mapper, and Roadkill Radar is compelling — the demand reset is permanent. Management's own workforce actions confirm they are not planning for recovery. The shift to IV push is clinical-evidence driven and unlikely to reverse. Additionally, hospital supply diversification efforts may be reducing BAX's share even as the market contracts. Pricing power is diminishing in 2026. The probability of positive organic growth in ITT is low — perhaps 20%.

Management is cutting workforce at the North Cove facility and explicitly described demand as a 'new baseline.' Companies do not cut manufacturing workforce when they expect demand recovery. Three lenses converged that the demand reset is permanent. Clinical practice changes have institutional inertia. Injectables declined 9% in Q4. This is a structurally declining segment and Q2 2026 is very unlikely to show positive organic growth.

The fundamental analysis is clear: demand has permanently declined. The only path to positive organic growth is favorable YoY comparisons if Q2 2025 was a particularly weak quarter during the initial demand reset. However, pricing contribution is also diminishing in 2026, so even if volumes stabilize, total organic revenue growth (volume + price) faces headwinds. I estimate about 20% probability.

The analysis is unambiguous: the IV Solutions demand reset is permanent. Management has acted on this belief by cutting manufacturing workforce. Hospital clinical protocols have changed. The shift from continuous IV infusion to IV push is reducing demand for BAX's core products. Positive organic growth requires volume recovery or significant pricing — neither appears likely. I assign 15% probability, reflecting only the small chance of favorable comparison effects or unexpected demand events.

Permanent demand reset per three-lens convergence. Management cutting workforce. Clinical practice changes embedded. Low probability of positive growth in Q2 2026.

Hospital fluid conservation is institutionalized. IV push utilization is increasing. Management acknowledges 'new baseline.' The segment is structurally declining. Positive organic growth very unlikely.

Small chance of positive organic growth through comparison effects or inventory restocking. But the fundamental analysis strongly points to continued decline. About 22% probability reflecting a small upside scenario.